CANY
NUVA

Caxton Associates (New York)’s NuVasive, Inc. NUVA Stock Holding History

Caxton Associates (New York)’s Portfolio NUVA Stock Details NUVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,700
Closed -$500K – 590
2017
Q1 		$500K Buy
+6,700
New +$486K ﹤0.01% 248

Other funds holding NUVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Caxton Associates (New York)'s NUVA Position: Q2 2017 in Review

Caxton Associates (New York) sold out of NuVasive, Inc. (NUVA) in Q2 2017, closing a stake of 6,700 shares — an estimated $500K sold.

Caxton Associates (New York) first reported a position in NUVA in Q1 2017 and held it in 1 quarter. The position peaked at $500K in Q1 2017. 298 funds tracked by Wall St. Rank hold NUVA as of Q2 2017.

  • Caxton Associates (New York) reported no remaining NuVasive, Inc. position as of Q2 2017 after selling out during the quarter.
  • Caxton Associates (New York) sold 6,700 NuVasive, Inc. shares in Q2 2017, an estimated $500K.
  • Caxton Associates (New York) first reported a position in NuVasive, Inc. in Q1 2017 and held it in 1 quarter.
  • Caxton Associates (New York)'s NuVasive, Inc. position peaked at $500K in Q1 2017.
  • 298 funds tracked by Wall St. Rank held NuVasive, Inc. as of Q2 2017.

Based on Caxton Associates (New York)'s 13F filing for Q2 2017, filed 14 Aug 2017.